THE SEMAGLUTIDE TREATMENT EFFECT IN PEOPLE WITH OBESITY: A REVIEW

ABSTRACT Background: Over 200 consequences, such as type 2 diabetes, cardiovascular disease, and shortened life expectancy, are linked to obesity, a chronic worldwide health issue. The effectiveness of current pharmaceutical weight-management treatments has been found to be limited. A glucagon-like peptide-1 (GLP-1) receptor agonist called semaglutide has shown promise as a therapy for overweight and obesity. Methods: Evidence from the Semaglutide Treatment Effect in People with Obesity is compiled in this review. We conducted a structured narrative review to summarize the current evidence on glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with obesity. Relevant studies were identified through a comprehensive search of PubMed, Embase and Scopus, using the keywords GLP-1 receptor agonists, semaglutide, safety, adverse events and obesity. Conclusion: Semaglutide 2.4 mg used once a week is a safe and efficient way for adults who are overweight or obese to manage their weight over time. Its strong effectiveness, cardiometabolic advantages, and manageable safety profile make it a revolutionary pharmaceutical treatment for obesity.